Vaxart, Inc.
Customers
1
1 federal agency
Suppliers
1
1 disclosed
Top supplier share
84%
of Kindred Biosciences, Inc. revenue · 3M to 2021-06-30
Top supplier by $
$3.0M
Kindred Biosciences, Inc. · 3M to 2021-06-30
Federal obligations
$9.3M
FY2024 · USAspending.gov
Latest period
Jun 30, 2021
10-Q filed 2021-08-05
Suppliers 1
Companies that disclose VXRT as a major customer, as a share of their own revenue. 1 active, 0 lapsed.
| Company | % of their revenue | Est. $ from VXRT | Period | Trend | Status | Source |
|---|---|---|---|---|---|---|
| Kindred Biosciences, Inc. Kindred Biosciences, Inc. |
84% | $3.0M | 3M 2021-06-30 | −14.0pp | Active | 10-Q 2021-08-05 |
Vaxart accounted for 84% and 93% of the contract manufacturing services we provided for the three and six months ended June 30, 2021, respectively. Vaxart accounted for 98% of the contract manufacturing services we provided in the first quarter of 2021. | ||||||
Federal contracts 1
Agencies that awarded contracts to this company, from USAspending.gov. Dollars are obligated amounts as reported, not estimates; $9.3M in the latest fiscal year shown per agency.
| Agency | Obligated | Fiscal year | Awards | Trend | Largest award |
|---|---|---|---|---|---|
| Department of Health and Human Services
Office of Assistant Secretary for Preparedness and Response |
$9.3M | FY 2024 | 1 | 75A50124C00002 | |
CLINICAL TRIAL PLANNING ACTIVITIES FOR A PHASE 2B CLINICAL TRIAL THAT COMPARES VAXART'S XBB VACCINE CANDIDATE TO AN MRNA COMPARATOR TO EVALUATE EFFICACY FOR SYMPTOMATIC AND ASYMPTOMATIC DISEASE, SYSTEMIC AND MUCOSAL IMMUNE INDUCTION, AND ADVERSE | |||||
Alerts are coming
Get an email when VXRT's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.